scholarly journals Cerebral dopamine neurotrophic factor is essential for enteric neuronal development, maintenance, and regulation of gastrointestinal transit

2020 ◽  
Vol 528 (14) ◽  
pp. 2420-2444
Author(s):  
Alcmène Chalazonitis ◽  
ZhiShan Li ◽  
Tuan D. Pham ◽  
Jason Chen ◽  
Meenakshi Rao ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Neuronal Development ◽  
Gastrointestinal Transit ◽  
Cerebral Dopamine Neurotrophic Factor ◽  
Cerebral Dopamine

scholarly journals Cerebral dopamine neurotrophic factor protects microglia by combining with AKT and by regulating FoxO1/mTOR signaling during neuroinflammation

2019 ◽  
Vol 109 ◽  
pp. 2278-2284 ◽  
Author(s):  
Yayun Zhang ◽  
Yanxiao Xiang ◽  
Xi Wang ◽  
Lin Zhu ◽  
Hao Li ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Mtor Signaling ◽  
Cerebral Dopamine Neurotrophic Factor ◽  
Cerebral Dopamine

scholarly journals Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington’s disease

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
P. Stepanova ◽  
V. Srinivasan ◽  
D. Lindholm ◽  
M. H. Voutilainen
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Quinolinic Acid ◽  
Neurotrophic Factor ◽  
Striatal Neurons ◽  
In Vivo Models ◽  
Cerebral Dopamine Neurotrophic Factor ◽  
Cerebral Dopamine

Abstract Huntington’s disease (HD) is a neurodegenerative disorder with a progressive loss of medium spiny neurons in the striatum and aggregation of mutant huntingtin in the striatal and cortical neurons. Currently, there are no rational therapies for the treatment of the disease. Cerebral dopamine neurotrophic factor (CDNF) is an endoplasmic reticulum (ER) located protein with neurotrophic factor (NTF) properties, protecting and restoring the function of dopaminergic neurons in animal models of PD more effectively than other NTFs. CDNF is currently in phase I–II clinical trials on PD patients. Here we have studied whether CDNF has beneficial effects on striatal neurons in in vitro and in vivo models of HD. CDNF was able to protect striatal neurons from quinolinic acid (QA)-induced cell death in vitro via increasing the IRE1α/XBP1 signalling pathway in the ER. A single intrastriatal CDNF injection protected against the deleterious effects of QA in a rat model of HD. CDNF improved motor coordination and decreased ataxia in QA-toxin treated rats, and stimulated the neurogenesis by increasing doublecortin (DCX)-positive and NeuN-positive cells in the striatum. These results show that CDNF positively affects striatal neuron viability reduced by QA and signifies CDNF as a promising drug candidate for the treatment of HD.

Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer's disease as well as in wild-type mice

2015 ◽  
Vol 291 ◽  
pp. 1-11 ◽  
Author(s):  
Susanna Kemppainen ◽  
Päivi Lindholm ◽  
Emilia Galli ◽  
Hanna-Maija Lahtinen ◽  
Henna Koivisto ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Transgenic Mice ◽  
Neurotrophic Factor ◽  
Long Term Memory ◽  
Wild Type ◽  
Term Memory ◽  
Cerebral Dopamine Neurotrophic Factor ◽  
Cerebral Dopamine
Sign in / Sign up

Export Citation Format

Share Document